1.Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China; 2.Outpatient Department of Traditional Chinese Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
Abstract：Objective To explore the medication rules of Director Shen Hongquan in the treatment of non-alcoholic fatty liver disease （NAFLD） based on the cloud platform of ancient and modern medical records. Methods A total of 143 patients with NAFLD treated by Director Shen Hongquan in the Outpatient Department of Putuo Hospital, Shanghai University of Traditional Chinese Medicine from December 2021 to December 2022 were selected as the study objects. Effective medical record data were collected and entered, and after standardized processing through the cloud platform of ancient and modern medical records, data mining was carried out on indicators such as drug frequency, nature, flavour, channel tropism distribution and correlation, cluster analysis, and complex network analysis, so as to summarize the medication rules of Director Shen Hongquan. Results A total of 143 prescriptions covering 300 kinds of traditional Chinese medicine. The drug nature were mainly calm, slightly cold, and warm. The drug flavours were bitter and sweet. The channel tropism were mainly liver channel and spleen channels. Crataegi Fructus, Nelumbinis Folium, Cassiae Semen, and so on were high-frequency drugs. The data of 18 association rules were obtained by association analysis of traditional Chinese medicine compatibility. Cluster analysis separated four groups of drugs, and complex network analysis identified 15 core drugs. Conclusion Director Shen Hongquan treated NAFLD with the principle of “soothing and softening liver, invigorating spleen for resolving turbidity”, reinforcement and elimination in combination, treating both the tip and root.
袁乙富1 沈红权2 张志丹2▲ 蒋元烨1▲. 基于数据挖掘探讨沈红权主任治疗非酒精性脂肪性肝病用药规律[J]. 中国医药导报, 2023, 20(29): 20-24.
YUAN Yifu1 SHEN Hongquan2 ZHANG Zhidan2▲ JIANG Yuanye1▲. Discussion on the medication rules of Director Shen Hongquan in the treatment of non-alcoholic fatty liver disease based on data mining. 中国医药导报, 2023, 20(29): 20-24.
[1] Powell EE，Wong VW，Rinell AM. Non-alcoholic fatty liver disease [J]. Lancet，2021，397（10290）：2212-2224. [2] Lazarus JV，Mark HE，Anstee QM，et al. Advancing the global public health agenda for NAFLD：a consensus statement [J]. Nat Rev Gastroenterol Hepatol，2022，19（1）：60-78. [3] Lazarus JV，Mark HE，Villota-Rivas M，et al. The global NAFLD policy review and preparedness index：Are countries ready to address this silent public health challenge? [J]. J Hepatol，2022，76（4）：771-780. [4] Younossi ZM. Non-alcoholic fatty liver disease-A global public health perspective [J]. J Hepatol，2019，70（3）：531- 544. [5] Estes C，Anstee QM，Arias-Loste MT，et al. Modeling NAFLD disease burden in China，France，Germany，Italy，Japan，Spain，United Kingdom，and United States for the period 2016-2030 [J]. J Hepatol，2018，69（4）：896-904. [6] Schattenberg JM，Lazarus JV，Newsome PN，et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018：A cost- of-illness analysis [J]. Liver Int，2021，41（6）：1227-1242. [7] O’Hara J，Finnegan A，Dhillon H，et al. Cost of non-alcoholic steatohepatitis in Europe and the USA：The GAIN study [J]. JHEP Rep，2020，2（5）：100142. [8] Paternostro R，Trauner M. Current treatment of non-alcoholic fatty liver disease [J]. J Intern Med，2022，292（2）：190-204. [9] Zhou Z，Zhang J，You L，et al. Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine [J]. Front Endocrinol（Lausanne），2022，13：1000727. [10] 何彦澄，肖永华，闫璞，等.中医医案分析方法评述[J].中医杂志，2018，59（13）：1106-1109. [11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018年更新版）[J].临床肝胆病杂志，2018，34（5）：947-957. [12] 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见（2017）[J].临床肝胆病杂志，2017， 33（12）：2270-2274. [13] 李军祥，陈润花，苏冬梅，等.中医药治疗非酒精性脂肪性肝病研究述评[J].世界华人消化杂志，2010，18（14）：1443-1451. [14] 李玉红，张伯礼，徐宗佩，等.脂肪肝中医药辨治系统评价[J].辽宁中医杂志，2002（11）：657-659. [15] 张桂红，孙建光，孙玉莉，等.从脏腑气化浅谈脂肪肝的中医病因病机[J].亚太传统医药，2019，15（5）：190-191. [16] 童光东，邢宇锋，周晓玲，等.肝癖（非酒精性脂肪性肝炎）诊疗方案[J].中国肝脏病杂志（电子版），2021，13（1）：1-9. [17] 杨上善.黄帝内经太素[M].北京：人民卫生出版社，1955. [18] 秦越人.难经[M].北京：科学技术文献出版社，2010. [19] 吴普.神农本草经[M].北京：人民卫生出版社，1963. [20] 李中梓.雷公炮制药性解[M].北京：人民军医出版社，2013. [21] Kim E，Jang E，Lee JH. Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases [J]. Nutrients，2022，14（4）：867. [22] 陶弘景.本草经集注[M].北京：人民卫生出版社，1994. [23] Yu LP，Li YQ，Li YJ，et al. In vivo identification of the pharmacodynamic ingredients of Polygonum cuspidatum for remedying the mitochondria to alleviate metabolic dysfunction-associated fatty liver disease [J]. Biomed Pharmacother，2022，156：113849. [24] Zhu LR，Li SS，Zheng WQ，et al. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy [J]. Front Immunol，2023， 14：1086078. [25] 叶天士.临证指南医案[M].上海：上海卫生出版社，1958. [26] 朱震亨.丹溪心法[M].北京：人民卫生出版社，2005.
2023, Vol. 20 
京公网安备 11010502046598号